Tailoring Treatment Strategies in Pancreatic Cancer: Prognostic Factors that Matter

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 16, 2016
Expiration Date: May 16, 2017

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will describe the use of molecular biomarkers to tailor personalized treatment strategies for patients with pancreatic cancer. Dr. Eileen M. O’Reilly, Medical Oncologist and Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreatic Cancer Research, provides insight into the future use of BRCA mutations to guide treatment with platinum-based therapies, in addition to other potential biomarkers, including C-reactive protein (CRP), hyaluronan (HA), and the use of immunogenic subgrouping to maximize outcomes from immune therapies.

Target Audience

This activity is designed for community oncologists, pharmacists, and allied health care professionals who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize ongoing clinical trial data related to the identification and development of current and potential biomarkers for use in pancreatic cancer

  • Identify potential linkage between biomarkers in pancreatic cancer with currently available, targeted treatments


Tailoring Treatment Strategies in Pancreatic Cancer: Prognostic Factors that Matter – Eileen M. O’Reilly, MD

Instructions for Participation and Credit

This activity is eligible for credit through May 16, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Eileen M. O’Reilly, MD
Associate Director for Clinical Research
David M. Rubenstein Center for Pancreas Cancer
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Eileen M. O’Reilly received her medical degree at Trinity College (Dublin University) in her native Ireland. She completed her residency training in Ireland and her fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. Dr. O’Reilly serves as the Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreas Cancer at MSKCC, where she is also an Attending Physician. In addition, Dr. O’Reilly is Professor of Medicine at Weill Cornell Medical College.

Nationally, Dr. O’Reilly is the chair of the Alliance Co-operative Group Gastrointestinal Cancers Committee, and serves on the Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas panel, and is on the board of the National Pancreas Foundation and ASCO IMT committee. Her institutional responsibilities include associate chairpersonship of the MSKCC Institutional Review & Privacy Board (IRB), membership of Research Council, and chair of the Continuing Medical Education (CME) committee.

Dr. O’Reilly is the Principal Investigator of multiple phase I, II and III trials in pancreas cancer and has authored/co-authored multiple articles, editorials and book chapters. Her major research focus and clinical activities include pancreatic and hepatobiliary malignancies, and her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy. In addition, Dr. O’Reilly teaches and mentors oncology fellows, junior faculty, residents and house-staff, and has won numerous teaching and other awards.


MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 0827-0000-16-088-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Eileen O’Reilly has received consultant fees from Aduro Biotech; Array BioPharma; Astellas Pharma US, Inc.; BioAlliance Pharma; Boston Scientific Corporation; Boston Therapeutics, Inc.; Bristol-Myers Squibb Company; CASI Pharmaceuticals Inc.; Celgene Corporation; Cipla; Eli Lilly and Company; EMD Serono, Inc.; Gilead; IntegraGen; MedErgy HealthGroup; MedImmune, LLC; Merrimack Pharmaceuticals, Inc.; Momenta Pharmaceuticals; Novartis AG; Onxeo; Pharmacyclics, Inc.; sanofi-aventis U.S. LLC; Silenseed LTD; SillaJen Biotherapeutics; and Vicus Therapeutics. She has received grant support related to research activities from Abbott Laboratories; Amgen Inc.; Bayer AG; CASI; Celgene; Eli Lilly; Exelixis, Inc.; Genentech, Inc.; ImClone Systems (a wholly-owned subsidiary of Eli Lilly and Company); Immunomedics, Inc.; Incyte Corporation; Momenta; Myriad Genetics, Inc.; Novartis; OncoMed Pharmaceuticals, Inc.; Polaris Group; and Vicus Therapeutics.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Alan J. Vogenberg, RPh, FASCP, Clinical Consultant, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Eileen M. O’Reilly has indicated that she does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Eileen M. O’Reilly has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved